Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
Sofie DeleuThomas N KakudaKurt SpittaelsJurgen J VercauterenVera HillewaertAmy LwinLorant LeopoldRichard M W HoetelmansPublished in: British journal of clinical pharmacology (2018)
Combination treatment with pimodivir and oseltamivir in healthy volunteers showed no clinically relevant drug-drug interactions. No safety concerns were identified with pimodivir 600 mg twice daily alone or in combination with oseltamivir 75 mg twice daily.